Floatz logo

Mercaptopurine Anhydrous

Down Syndrome

National Cancer Institute (NCI)Small moleculePhase 3Active
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

33 Active assets in the Down Syndrome cohort.

Asset / SponsorPhaseRating
Vincristine Sulfate
National Cancer Institute (NCI)
Phase 3BB
Pegaspargase
National Cancer Institute (NCI)
Phase 3BB
Methotrexate
National Cancer Institute (NCI)
Phase 3BB
Cytarabine
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 3BB
Blinatumomab
National Cancer Institute (NCI)
Phase 3BB

View all 35 →

Same molecule, other indications

Mercaptopurine Anhydrous is also rated in:

adult acute lymphoblastic leukemiaActive
A
Indicative · Phase 4
81 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
A
Indicative · Phase 3
80 / 100
View asset →
childhood acute lymphoblastic leukemiaActive
BBB
Indicative · Phase 3
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →